# Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus

> **NCT00529321** · PHASE1 · COMPLETED · sponsor: **Transgene** · enrollment: 42 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** MVA-HCV (Immunotherapy)

## Key facts

- **NCT ID:** NCT00529321
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-09
- **Final completion:** 2010-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2010-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529321, "Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00529321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*